Courtship in the clinic: Seagen unveils positive bladder cancer data for Padcev-Keytruda combo amid merger talks with Merck

Seattle-based biotech company Seagen recently released early findings from a trial of its drug Padcev in combination with Merck‘s Keytruda to treat patients with specific forms of urothelial cancer.

The data surpassed researchers’ bar for success with a 64.5 percent response rate, indicating a possible fast-track to FDA approval. Padcev is currently in development for various forms and settings of bladder cancer and involved in a solid tumor trial as well.

READ THE STORY at Fierce Pharma»